𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

✍ Scribed by R. Pearce; M. Heikkilä; I.-B. Lindén; P. Jenner

Book ID
105885203
Publisher
Springer
Year
2001
Tongue
English
Weight
66 KB
Volume
156
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Repeated administration of piribedil ind
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation
✍ Lance A. Smith; Banu C. Tel; Michael J. Jackson; Matthew J. Hansard; Rogelio Bra 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 615 KB

## Abstract Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D~2~/D~3~ dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal g

De novo administration of ropinirole and
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
✍ Ronald K. B. Pearce; Tara Banerji; Professor Peter Jenner; C. David Marsden 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 760 KB

## Abstract In contrast to levodopa (L‐dopa), de novo administration of the D2‐like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated subhuman primates is not associated with the onset of significant dyskinesia

Idazoxan, an alpha-2 antagonist, and L-D
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc